- Home
- HTH vs IMCR Comparison
HTH vs IMCR Comparison
Compare HTH & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTH
- IMCR
- Stock Information
- Founded
- HTH 1998
- IMCR 2008
- Country
- HTH United States
- IMCR United Kingdom
- Employees
- HTH N/A
- IMCR N/A
- Industry
- HTH Major Banks
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HTH Finance
- IMCR Health Care
- Exchange
- HTH Nasdaq
- IMCR Nasdaq
- Market Cap
- HTH 2.1B
- IMCR 1.7B
- IPO Year
- HTH 2004
- IMCR 2021
- Fundamental
- Price
- HTH $31.28
- IMCR $28.95
- Analyst Decision
- HTH Hold
- IMCR Buy
- Analyst Count
- HTH 3
- IMCR 13
- Target Price
- HTH $34.50
- IMCR $65.18
- AVG Volume (30 Days)
- HTH 230.1K
- IMCR 246.4K
- Earning Date
- HTH 01-23-2025
- IMCR 11-06-2024
- Dividend Yield
- HTH 2.18%
- IMCR N/A
- EPS Growth
- HTH N/A
- IMCR N/A
- EPS
- HTH 1.63
- IMCR N/A
- Revenue
- HTH $1,169,826,000.00
- IMCR $296,312,000.00
- Revenue This Year
- HTH N/A
- IMCR $29.19
- Revenue Next Year
- HTH $0.79
- IMCR $12.56
- P/E Ratio
- HTH $19.13
- IMCR N/A
- Revenue Growth
- HTH N/A
- IMCR 25.09
- 52 Week Low
- HTH $28.58
- IMCR $28.17
- 52 Week High
- HTH $35.66
- IMCR $76.98
- Technical
- Relative Strength Index (RSI)
- HTH 44.12
- IMCR 33.78
- Support Level
- HTH $31.01
- IMCR $28.17
- Resistance Level
- HTH $32.04
- IMCR $29.91
- Average True Range (ATR)
- HTH 0.61
- IMCR 1.34
- MACD
- HTH -0.08
- IMCR -0.30
- Stochastic Oscillator
- HTH 10.83
- IMCR 18.30
About HTH Hilltop Holdings Inc.
Hilltop Holdings Inc is a Dallas-based financial holding company. Its primary line of business is to provide business and consumer banking services from offices throughout Texas through the PlainsCapital Bank. The company also provides other financial products and services through its broker-dealer and mortgage origination segments. The company generates a majority of its revenue through its banking operations.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.